<DOC>
	<DOCNO>NCT00004006</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Bone marrow transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus radiation therapy follow bone marrow transplantation treat patient retinoblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy , Radiation Therapy , Bone Marrow Transplantation Treating Patients With Retinoblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate feasibility sequential therapy carboplatin , etoposide , cyclophosphamide , doxorubicin , topotecan radiotherapy follow autologous bone marrow transplantation patient extrachoroidal metastatic retinoblastoma . - Assess treatment regimen term response toxicity autologous bone marrow transplantation patient population . OUTLINE : Patients receive carboplatin IV day 1 etoposide IV 1 hour daily day 1-3 week 0 , 6 , 12 , plus cyclophosphamide IV orally daily day 1-7 , doxorubicin IV day 8 carboplatin IV 1 hour day 10 week 3 , 9 , 15 . Beginning week 6 , patient receive concurrent radiotherapy 5 day week 4-6 week . Patients meningeal involvement receive topotecan intrathecally twice weekly 3 week weekly 3 week start radiotherapy . Beginning one day treatment course , patient receive filgrastim ( G-CSF ) subcutaneously daily 10 day . Patients undergo bone marrow collection week 6 . Following hematologic recovery , patient receive several day high dose chemotherapy consist cyclophosphamide topotecan follow bone marrow reinfusion . Patients follow 6 , 9 , 12 month , every 6 month 4 year . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis extrachoroidal metastatic retinoblastoma , confirm histology , physical examination , diagnostic imaging PATIENT CHARACTERISTICS : Age : 15 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior chemotherapy low stage intraocular disease allow Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy except eye ( ) orbit ( ) Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>intraocular retinoblastoma</keyword>
	<keyword>extraocular retinoblastoma</keyword>
	<keyword>recurrent retinoblastoma</keyword>
</DOC>